Publications in collaboration with researchers from Hospital Juan Ramón Jiménez (19)

2022

  1. Study protocol for a randomized clinical trial to assess 7 versus 14-days of treatment for Pseudomonas aeruginosa bloodstream infections (SHORTEN-2 trial)

    PLoS ONE, Vol. 17, Núm. 12 December

2021

  1. Clinical Characteristics and Risk Factors of Respiratory Failure in a Cohort of Young Patients Requiring Hospital Admission with SARS-CoV2 Infection in Spain: Results of the Multicenter SEMI-COVID-19 Registry

    Journal of General Internal Medicine, Vol. 36, Núm. 10, pp. 3080-3087

  2. Gender-based differences by age range in patients hospitalized with covid-19: A spanish observational cohort study

    Journal of Clinical Medicine, Vol. 10, Núm. 5, pp. 1-21

  3. Healthcare workers hospitalized due to COVID-19 have no higher risk of death than general population. Data from the Spanish SEMI-COVID-19 Registry

    PLoS ONE, Vol. 16, Núm. 2 February

  4. Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry

    Drugs, Vol. 81, Núm. 6, pp. 685-695

  5. Use of antihyperglycaemic therapy with cardiovascular benefit in patients with type 2 diabetes who require hospitalisation: A cross-sectional study

    Revista Clinica Espanola, Vol. 221, Núm. 9, pp. 517-528

2020

  1. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 10, pp. 657-676

  2. Role of age and comorbidities in mortality of patients with infective endocarditis

    European Journal of Internal Medicine, Vol. 64, pp. 63-71

2018

  1. Derivation and validation model for hospital hypoglycemia

    European Journal of Internal Medicine, Vol. 47, pp. 43-48

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2015

  1. Current epidemiology and outcome of infective endocarditis: A multicenter, prospective, cohort study

    Medicine (United States), Vol. 94, Núm. 43

  2. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

2011

  1. Retraso diagnóstico de la infección por el VIH en Andalucía

    Enfermedades Infecciosas y Microbiologia Clinica

2006

  1. Enfermedad de Fabry en España: Primer análisis de la respuesta al tratamiento de sustitución enzimática

    Medicina Clinica, Vol. 127, Núm. 13, pp. 481-484

2005

  1. Molecular epidemiology of HTLV-2 infection among intravenous drug users in Spain

    Journal of Clinical Virology, Vol. 33, Núm. 1, pp. 65-70

2001

  1. Multicenter randomized study comparing initial daily induction with high dose lymphoblastoid interferon vs. standard interferon treatment for chronic hepatitis C

    Journal of Medical Virology, Vol. 64, Núm. 4, pp. 460-465

1997

  1. Multicenter randomized, controlled study of intramuscular administration of interferon-β for the treatment of chronic hepatitis C

    Journal of Interferon and Cytokine Research, Vol. 17, Núm. 1, pp. 27-30

  2. Tolerance and efficacy of subcutaneous interferon-β administered for treatment of chronic hepatitis C

    Journal of Interferon and Cytokine Research, Vol. 17, Núm. 2, pp. 65-67